Part 2
Part 1 of this article addressed the issue of partially inoculating a broader population due to limitations in the vaccine supply. Read More
Latest News
Few vaccine responders with fingolimod, ocrelizumab
April 23, 2021Most MS patients currently treated with fingolimod or ocrelizumab will fail to mount an immune response to COVID-19 vaccination, according to the results of the first real-world study of vaccine response in MS patients on disease-modifying therapies (DMT) (Achiron et al. Ther Adv Neurol Disord 2021:14:1-8). An adequate vaccine response was seen in cladribine-treated patients. Read More
AAN Daily Reports – Wednesday, April 21 edition
April 21, 2021American Academy of Neurology annual meeting – April 17-22, 2021
Tuesday, April 20 edition
Monday, April 19 edition
CONGRESS HIGHLIGHTS – WEDNESDAY EDITION Read More
AAN 2021 Poster Picks – Day 3
April 21, 2021AAN 2021 Poster Picks – Day 2
AAN 2021 Poster Picks – Day 1
Poster 150 – Characterizing 1-Year Development of Cervical Cord Atrophy Across Different MS Phenotypes: A Voxel-Wise, Multicenter Analysis
Massimo Filippi, MD
Objective: Evaluate the change in cervical cord atrophy over time. Read More